Cerebrovascular events after discontinuation of rofecoxib treatment.
Andersohn
Frank
F
D002545:Brain Ischemia / Q000139:chemically induced* / Q000453:epidemiology; D052246:Cyclooxygenase 2 Inhibitors / Q000008:administration & dosage / Q000009:adverse effects* / Q000627:therapeutic use; D006801:Humans; D015994:Incidence; D007783:Lactones / Q000008:administration & dosage / Q000009:adverse effects* / Q000627:therapeutic use; D012306:Risk; D020521:Stroke / Q000139:chemically induced* / Q000453:epidemiology; D013450:Sulfones / Q000008:administration & dosage / Q000009:adverse effects* / Q000627:therapeutic use
D052246:Cyclooxygenase 2 Inhibitors; D007783:Lactones; D013450:Sulfones; C116926:rofecoxib